Browse by author
Lookup NU author(s): Pooja Prasad, Dr Ashwin Sivaharan, Dr Maziar Navidi, Professor Michael Griffin, Professor Alexander PhillipsORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2022 Elsevier Inc. Background: Neoadjuvant chemotherapy is established in the treatment of gastric adenocarcinoma. Histopathological regression may have important prognostic implications. There are little data comparing clinical outcomes of patients with gastric adenocarcinoma that received neoadjuvant treatment and those neoadjuvant naive. The aim of this study is to determine the impact of neoadjuvant chemotherapy upon prognosis of patients being treated for gastric adenocarcinoma. Methods: Consecutive patients with gastric cancer from a single center between 2007 and 2017 were evaluated. Patients were treated with either a subtotal or total gastrectomy with D2 lymphadenectomy. Stage-by-stage comparison of the extent of pathological downstaging was conducted for patients who received neoadjuvant treatment (ypTNM) and those who did not (pTNM) using the TNM eighth edition. Results: Overall, 384 patients underwent gastrectomy, 141 patients received neoadjuvant chemotherapy, and 86 patients (58.1%) were downstaged. Downstaged patients had improved overall survival compared to patients who did not respond to neoadjuvant chemotherapy (not reported vs 66 months, P < .001). Downstaging by >3 stages was the strongest independent predictor of overall survival (hazard ratio: 0.17; 95% confidence interval 0.062–0.44). Overall survival was significantly better among patients in the ypTNM groups when a stage-by-stage comparison was performed with the pTNM group. Conclusion: Pathological stage is a more accurate predictor of prognosis compared clinical stage with downstaged patients benefiting from lower recurrence rates and improved overall survival. Patients downstaged due to neoadjuvant chemotherapy may potentially have more favorable clinical outcomes compared to stage-matched patients who did not receive this.
Author(s): Prasad P, Sivaharan A, Navidi M, Fergie BH, Griffin SM, Phillips AW
Publication type: Article
Publication status: Published
Journal: Surgery
Year: 2022
Volume: 172
Issue: 2
Pages: 593-601
Print publication date: 01/08/2022
Online publication date: 07/04/2022
Acceptance date: 03/03/2022
ISSN (print): 0039-6060
ISSN (electronic): 1532-7361
Publisher: Elsevier Inc.
URL: https://doi.org/10.1016/j.surg.2022.03.005
DOI: 10.1016/j.surg.2022.03.005
Altmetrics provided by Altmetric
